FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours By Ogkologos - September 2, 2026 52 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-001 and LIBRETTO-121 studies Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Stopping the spread: A revolution in how we think about metastasis October 18, 2022 Taking Control – Risks vs. Benefits July 14, 2020 Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer January 7, 2019 The right combination for early detection August 4, 2021 Load more HOT NEWS FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma,... Hospice Nurse Fired from Job After Being Diagnosed with Breast Cancer Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with...
